Pages that link to "Q37940567"
Jump to navigation
Jump to search
The following pages link to Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. (Q37940567):
Displaying 50 items.
- Management of diabolical diabetes mellitus and periodontitis nexus: Are we doing enough? (Q26766648) (← links)
- Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus (Q33607764) (← links)
- Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine (Q34395551) (← links)
- Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial (Q34543042) (← links)
- Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial (Q35225372) (← links)
- Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health Survey (Q35604695) (← links)
- Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease (Q35717211) (← links)
- SGLT-2 Inhibitors: A New Mechanism for Glycemic Control (Q35906490) (← links)
- Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis (Q36073425) (← links)
- Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis (Q36073438) (← links)
- Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin (Q36169413) (← links)
- Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise (Q36441684) (← links)
- Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012 (Q36818863) (← links)
- Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial (Q36820255) (← links)
- Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial (Q37263232) (← links)
- How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment (Q37577129) (← links)
- Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin (Q37718287) (← links)
- The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis (Q37984756) (← links)
- Humalog (lispro) for type 2 diabetes (Q38050151) (← links)
- Composite endpoints in trials of type-2 diabetes (Q38154679) (← links)
- Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients. (Q38163894) (← links)
- Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. (Q38212472) (← links)
- Empagliflozin for the treatment of type 2 diabetes (Q38258643) (← links)
- Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. (Q38568342) (← links)
- New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin (Q38640170) (← links)
- Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. (Q38712728) (← links)
- Reporting of Sex Effects by Systematic Reviews on Interventions for Depression, Diabetes, and Chronic Pain (Q38816672) (← links)
- Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis (Q38907259) (← links)
- Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients? (Q39812306) (← links)
- Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study). (Q40363925) (← links)
- Premixed insulin regimens in type 2 diabetes: pros. (Q40839083) (← links)
- Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? (Q43785600) (← links)
- Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial (Q43809926) (← links)
- Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes (Q47443616) (← links)
- Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes. (Q48189728) (← links)
- Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study (Q50035868) (← links)
- Identifying insulin treatment responders with a composite measure: beyond Hba1c < 7% in patients with type 2 diabetes (Q50077356) (← links)
- Heterogeneity of Clinical Trials for Antihypertensive Drugs in Japan: Exploratory Analysis of Confirmatory Phase III Trials Used for Marketing Approval (Q50086673) (← links)
- Mediterranean diet for type 2 diabetes: cardiometabolic benefits (Q50235713) (← links)
- Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers (Q50454359) (← links)
- The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. (Q53449720) (← links)
- Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). (Q53519441) (← links)
- Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. (Q53726559) (← links)
- Prevalence of musculoskeletal pain in association with serum 25-hydroxyvitamin D concentrations in patients with type 2 diabetes mellitus. (Q55190271) (← links)
- Clinical outcomes of an integrated primary-secondary model of care for individuals with complex type 2 diabetes: a non-inferiority randomised controlled trial (Q57035922) (← links)
- Motivating people to sustain healthy lifestyles using persuasive technology: A pilot study of Korean Americans with prediabetes and type 2 diabetes (Q58599155) (← links)
- Factors that Correlate with Poor Glycemic Control in Type 2 Diabetes Mellitus Patients with Complications (Q58805293) (← links)
- Baseline Glycated Hemoglobin Values Predict the Magnitude of Glycemic Improvement in Patients with Type 1 and Type 2 Diabetes: Subgroup Analyses from the DIAMOND Study Program (Q58806286) (← links)
- Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither? (Q58828945) (← links)
- Exploratory analysis of comparative clinical trials used for marketing approval in patients with type 2 diabetes in Japan (Q60918003) (← links)